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CLINICAL INVESTIGATION
Gianturco self-expanding stent in the treatment of stenosis in
dialysis access grafts
GERALD A. BEATHARD
Austin Diagnostic Clinic, Austin, Texas, USA
Gianturco self-expanding stent in the treatment of stenosis in dialysis
access grafts. This study evaluated the effectiveness of the Gianturco
endovascular stent in preserving graft patency following percutaneous
transvenous angioplasty (PTVA) of stenotic lesions occurring at the
graft-vein anastomosis in hemodialysis patients with polytetrafluoro-
ethylene grafts. Fifty-eight patients having 50% or greater stenosis were
randomly divided into a treatment group (N = 28) and a concurrent
control group (N = 30) following PTVA. In the treatment group, a stent
was placed following dilatation. Graft thrombosis, the need for surgical
revision, or the need for a repeat PTVA were used as end point events.
The period of time from the PTVA/stent procedure to the end point
event was referred to as the duration of efficacy (DE). By life table
analysis, the DE for the treatment group was 100% at 30 days, 91% at
60 days, 85% at 90 days, 72% at 180 days, and 17% at 360 days.
Comparison of the characteristics and results obtained in the treatment
group and that of the concurrent control group revealed no significant
difference in any parameter prior to treatment, in the response to
PTVA, or in the DE of the procedure performed. It was concluded that
the stent offered no advantage in the treatment of the graft-vein
anastomosis stenotic lesion affecting PTFE dialysis access grafts.
Maintenance of an adequate vascular access for hemodialysis
is a major problem in the care of patients with end-stage renal
disease. The placement and management of complications of
vascular access account for approximately one-fourth of all
admissions and hospitalization days for hemodialysis patients
[1—3]. The problem is greatest for patients with polytetrafiuo-
roethylene (PTFE) grafts. In these cases, the cumulative pa-
tency rate is only 67 to 83% at one year [4, 5]. The most
common cause for graft loss is partial or complete obstruction
due to thrombosis, stenosis or both [5].
Stenotic lesions leading to obstruction and loss of patency
may affect the graft, graft-vein anastomosis or veins draining
the graft up through the subclavian. These lesions may be
successfully treated by either surgical revision or by percuta-
neous transvenous angioplasty (PTVA). Unfortunately, with
either form of therapy the recurrence rates are high. The
patency rate at 12 months following the first access site surgical
revision has been reported to be 15 to 36%, depending upon the
surgical technique used [6—8]. In a large series of patients with
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stenosis treated by PTVA, 38% of grafts were patent at one year
[9].
Attempts to prolong graft patency through the use of endo-
vascular metallic stents have been reported [10—13]. Unfortu-
nately, it is not possible to draw meaningful conclusions from
these studies because they are all either preliminary, too small,
uncontrolled, or involve a very heterogeneous group of lesions.
The purpose of this report is to present controlled data on a
homogeneous group of stented dialysis access grafts with
long-term follow-up.
Methods
Design of the study
Only dialysis patients with stenosis at the PTFE graft-vein
anastomosis were considered for this study (Fig. lA). Fifty-
eight patients were enrolled; all of these had 50% or greater
stenosis determined radiographically. After giving informed
consent, the patients were randomly assigned to either the
treatment group or the concurrent control group. Both of these
groups were treated with PTVA and followed in an identical
manner, except that in the treatment group a stent was placed
across the previously stenotic site immediately following
PTVA. A patient was excluded from the study if the stenotic
lesion could not be dilated to 100% of normal vessel diameter by
the PTVA procedure.
Thirty stents were placed in 28 patients during the study. The
concurrent control group consisted of 30 patients. A historical
control group of 185 patients was also used for comparison.
The treatment and concurrent control groups were compara-
ble in all of their demographic characteristics. The records of all
of the patients in the study were reviewed to determine the age
of their grafts, any previous invasive procedures that had been
performed, and the time interval between the occurrence of
such procedure and entry into the study (Tables 3 and 4).
The stent
The Gianturco or Z stent [14] was used in this study. This is
a self-expanding stent constructed from tempered stainless steel
wire 0.010 inch in diameter. This was first bent into a zig-zag
configuration; the two ends were then connected using silver
solder to form a cylinder 1.5 x 1.5 cm in size. Two of these
elements were joined by a single strut to form a stent unit 3 cm
in length and 1.5 cm in diameter (Fig. 1B).
In the first 11 cases of the study a regular stent design with a
rigid strut and no barbs was used. In the remaining 17 patients,
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Fig. 1A. Radiograph of lesion (arrow) marked with cutaneous needle prior to PTVA. B. Expanded stent (arrow) in place across lesion after PTVA.
C. Venogram of vessel with stent (arrow) in place demonstrating no obstruction to flow.
the rigid strut was replaced with one that was hinged in the
middle so that the two elements could articulate and provide
flexibility to the unit. This was felt to be desirable because many
of these lesions were located at the elbow. Additionally, in
these modified stents, barbs or hooks were added to anchor the
stent to the vessel wall and prevent migration.
Stent placement
The stenotic lesion was first treated by PTVA using a
standard technique [9]. Stent placement was performed imme-
diately afterwards. The stent was loaded into the distal end of a
long, 7F, thick-walled, teflon sheath and pushed through to the
tip with an obturator. The sheath had been cut to a length
appropriate to reach the lesion in the individual patient. The
stent was discharged from the sheath so that it would lie across
the previously stenotic site which had been marked prior to
PTVA with a cutaneous needle (Fig. lA). A venogram was
performed immediately after stent placement to evaluate place-
ment and blood flow through the site of the lesion (Fig. 1C).
No anticoagulant was used at the time of or after stent
placement. No difficulties were encountered with stent place-
ment, except that in two patients the position of the stent was
not felt to be optimum. In these two cases, a second stent was
placed.
Follow-up
Follow-up in this study consisted of observation for the
occurrence of complications (Table 3), monitoring of venous
pressure measured on dialysis (VPm) after the procedure (Table
I), and observation to determine the duration of efficacy (DE) of
the treatment (Table 2). Repeat venograms were performed
only when clinically indicated.
Since VPm has been shown to be of value in the detection of
Table 1. Venous pressure (VPm)
Pretreatmenta
Category mm Hg
% Decrease post-PTVA/stent
I week" I monthb 3 month"
Stentgrouplc 106±34 38±17 30±25 35±26(N=28)
Stentgroup2 106±35 40±16 32±21 31±22(N = 26)
Concurrent control 108 27 37 20 26 22 24 20
(N = 30)
Historical control 115 36 36 26 32 27 27 31
(N = 185)
a Pre-treatment differences between categories were not significant
(P = 0.3)b Differences at these time intervals compared to pre-treatment
values were significant for all groups (P = 0.001)
" Stentgroup 1—all cases, stent group 2—excludes two cases with stent
migration
graft stenosis [9, 13, 15, 16], it was monitored continuously at
each dialysis treatment following the PTVA/stent procedure for
the entire period that the stented graft continued to be func-
tional. An average VPm was tabulated at one week, one month,
and three months following the procedure for the purpose of
comparison between groups (Table 1). All readings were made
according to a standardized technique [91. This consisted of
measuring the VPm early in dialysis (5 mm) at a blood flow of
200 cc/mm using a standard sized dialysis needle (16 gauge).
Measurements were recorded for three consecutive dialysis
treatments at each of the three time intervals indicated. The
average of these three values was compared to the pre-treat-
ment VPm, which was defined as the average of six standard-
ized readings recorded at the time of the six consecutive
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Table 2. Duration of efficacy (DE)
Category
Time period days
30 60 90 180 360
Stent group 1
Stent group 2
Concurrent control
Historical control
100
100
93
96
91
96
89
92
85
92
79
84
72
82
64
67
17
19
28
44
Data represent percentage of cases surviving at each time interval
determined by life table analysis.
a Differences when compared to control groups not significant at any
time interval (P = 0.07 to 0.1)
dialysis treatments immediately prior to the VFVAIstent proce-
dure. This comparison was used to determine the percent
change in VPm produced by the treatment.
Duration of efficacy (DE) for the procedure was defined as
the period of time that elapsed until the treated access throm-
bosed, required surgical revision, or required a repeat PTVA.
Repeat PTVA procedures were performed in the routine
manner through the stent. The positioning of the stent was not
disturbed. When the balloon was withdrawn from the stent
following dilatation, the catheter was rotated to avoid entangle-
ment.
Controls and subgroups
The results obtained in the treatment group were considered
in two ways: stent group 1 represented all cases, and in stent
group 2, the two cases experiencing migration were excluded.
Additionally, the treatment group was divided into two sub-
groups, those with regular and those with modified stents.
These subgroups were compared separately with each other
and with both the concurrent and historical control groups.
The historical control group consisted of 185 patients with the
same lesion type and severity. These patients had been treated
and followed in the same manner as described in this study.
All the patients in the each group discussed in this paper had
only the lesion at the graft-vein anastomosis and all had 50% or
greater stenosis. While all cases in the treatment and concurrent
control groups had 100% dilatation with PTVA, only 80% of the
historical control group had this degree of success.
Statistical analysis
The Kaplan-Meier method was used to calculate the life table
analysis data. Comparisons of DE for different groups were
made using the generalized Wilcoxon test for comparing data
derived from life table analysis involving censored observa-
tions. Comparisons between the VPm measured at different
time intervals for the same group were analyzed using the
Wilcoxon signed rank test for nonparametric data involving
paired samples. To compare VPm differences noted between
different groups the Wilcoxon rank sum test was used. The
chi-square test was utilized to determine statistical significance
of differences in end point event between the treatment and
concurrent control groups. In all instances a probability value
of 0.05 or less was used to determine statistical significance.
Results
A comparison of pre-treatment VPm for the treatment group,
the concurrent control group and the historical groups (Table 1)
showed no significant difference (P = 0.3). The mean age of
grafts in the treatment group (Table 3) was 19.4 8.7 months
(median 19.5 months), while that of the concurrent control
group 21.3 14 (median 20.7 months). This difference was not
significant (P = 0.3).
Eighteen of the treatment group had had a previous proce-
dure performed on their grafts (Table 3). Twenty-two of the
concurrent control group had had previous procedures (Table
4). These differences were not significant (P = 0.6).
Placement of the stent was accomplished without difficulty
and without any immediate complication. A second stent was
placed in each of two patients in order to achieve optimum
placement. Two delayed complications occurred. In case 1, the
stent moved at one week post-placement causing immediate
discomfort. One leg of the stent had perforated the vessel. This
caused no problem except for continued discomfort when the
patient flexed the arm. Radiographically, the stent was no
longer across the site of the lesion. The stent was removed at 44
days, In case 10, the patient experienced sudden pain and
swelling around the vein above the graft-vein anastomosis
following a fall in which the area was struck. Radiographically,
the stent was found to have moved. It was no longer across the
site of the lesion, but was within the swollen area which was
found at surgery to be a hematoma. This occurred 57 days after
placement.
Two patients of the treatment group expired during the
course of the study. In neither case did the study contribute to
the cause of death.
The presence of the stent within the vessel produced no
radiographic evidence of intraluminal narrowing or obstruction
(Fig. 1C). This was also confirmed by the VPm data post-
treatment. The decrease in the VPm (Table 1) for the treatment
group compared to the pre-treatment value for that group was
significant at all three time intervals (P = 0.001). This was also
true for both of the control groups. Comparison of these values
showed no significant difference between the treatment group
and either of the control groups (P = 0.3).
The DE for each of the groups in this study is shown in Table
2. For stent group 2 (migration cases excluded), life table
analysis showed a DE of 100% at 30 days, 96% at 60 days, 92%
at 90 days, 82% at 180 days, and 19% at 360 days. In three
patients, the grafts were continuing to be patent and functioning
adequately at 374, 570, and 604 days. When the DE data for
stent group 1 and stent group 2 was compared to the concurrent
and to the historical control groups, a numerical superiority was
seen for the stented cases during the first 180 days. At 360 days,
however, this relationship had reversed. These differences were
not statistically significant at either 180 or 360 days (P 0.07 to
0.1).
When the data for those patients with regular stents only or
those with modified stents only was compared to the control
groups, no significant difference in DE was noted (P 0.7 to
0.1).
Evaluation of the causes of loss of individual cases in the
study (end-point event; Tables 3 and 4) showed no significant
differences between the stented cases and either the concurrent
control (P = 0.5) or historical control groups (P = 0.1).
Follow-up venograms were performed in 16 patients. In 10
cases, narrowing of the vessel lumen within the stent was
observed. There was no narrowing or compression of the stent
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Table 3. Summary of stent cases
Duration
Case #
Age of graft
months
Previous
procedure
Intervala
months
Stent
type Complication
End point
event
of efficacy
days
1 18 none — regular migration surgery 44
2 15 angioplasty 7 regular none angioplasty 137
3 20 none — regular none died 63
4 32 thrombectomy 8 regular none thrombosis 519
5 28 thrombectomy 2 regular none thrombosis 176
6 24 angioplasty 5 regular none angioplasty 225
7 24 angioplasty 8 regular none angioplasty 197
8 17 none — regular none died 123
9 20 thrombectomy 19 regular none thrombosis 258
10 7 revision 1 regular migration surgery 57
11 23 angioplasty 6 regular none angioplasty 272
12 21 angioplasty 16 modified none angioplasty 239
13 7 none — modified none thrombosis 349
14 20 thrombectomy 1 modified none angioplasty 231
15 21 none — modified none LTFb 46
16 16 none — modified none LTF 96
17 19 none — modified none angioplasty 62
18 39 thrombectomy 34 modified none (patent) 604
19 10 none — modified none thrombosis 237
20 12 angioplasty 4 modified none angioplasty 98
21 34 revision 24 modified none (patent) 570
22 4 none — modified none angioplasty 341
23 14 thrombectomy 8 modified none thrombosis 234
24 32 angioplasty 8 modified none angioplasty 273
25 9 none — modified none thrombosis 368
26 28 angioplasty 8 modified none thrombosis 351
27 13 thrombectomy 5 modified none thrombosis 185
28 17 thrombectomy 1 modified none (patent) 374
a Interval between previous procedure and stent
b LTF lost to follow-up
itself, however. This narrowing was smooth, tapered at each
end and at times extended a short distance into the vein
proximal (upstream) to the stent. In the two cases experiencing
stent migration, venograms were performed because of that
complication. In the remaining four cases in which venograms
were performed, the appearance of the stent and vessel was
essentially as it had been at the time of placement. These were
done at 62, 86, 88 and 360 days. In two of these cases, stenotic
lesions were present within the vein proximal (upstream) to the
stent. These new lesions were separate from and some distance
from the stented lesion. They were not counted as losses to the
study. This was also the case in four of the patients of the
concurrent control group. As previously reported [9], in one-
third of cases in the historical control group, when a repeat
PTVA was required it was for a new lesion rather than a
recurrence of the old one.
In the 10 cases having stenotic lesions within the stent, repeat
PTVA procedures were performed. All of these cases had had
an elevated VPm which had been the indication for the proce-
dure. No problems were encountered in any of these repeat
procedures. In no case was stent position affected. The results
of these repeat treatments were comparable to the primary
procedure.
In four cases, the intraluminal material causing the stenosis
appeared to be soft, disappearing very easily and quickly
without causing an indentation in the inflated angioplasty bal-
loon. This was unlike the appearance noted in the other cases
presumed to have intraluminal pseudointimal hyperplasia.
All surgical revisions, except for the two cases with stent
migration, were performed following graft thrombosis. Throm-
bectomy using a Fogarty catheter generally resulted in loss of
the stent due to entanglement of the apparatus by the balloon as
it was being withdrawn.
Discussion
The majority of patients receiving hemodialysis in the United
States today are able to do so because of the availability of
polytetrafluoroethylene (PTFE) grafts. Unfortunately these
grafts, used as vascular access for hemodialysis, have a limited
life expectancy [5, 6]. With the expanding size of the dialysis
population and the expectation of longer life expectancy on
dialysis, the problem of limited durability of the vascular access
will continue to increase in importance.
Early recognition and treatment of the problems resulting in
graft loss has been emphasized as a means of increasing graft
survival [15, 161. Even an aggressive approach, however, does
not result in a long-term solution because the problems are
recurrent regardless of the mode of therapy [4—9].
The evaluation of new alternative means of therapy designed
to remedy or prevent recurrence of the problems leading to
graft loss warrant careful evaluation. One of these therapies is
the insertion of an endovascular stent following the PTVA
treatment of a stenotic lesion, a leading cause of dialysis access
graft loss. This therapy has been the subject of several reports
[10—13]. Unfortunately, the data presented in these reports is
not conclusive.
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Table 4. Summary of control cases
Case #
Age of graft
months
Previous
procedure
Interva1
months
End point
of efficacy
Duration
days
15 angioplasty 7 revision
2 20 none — (patent)
3 9 thrombectomy 1 thrombectomy
4 9 none — thrombectomy
5 33 thrombectomy 1 thrombectomy
6 22 angioplasty 5 angioplasty
7 18 thrombectomy 1 LTFb
8 19 thrombectomy 8 died
9 30 revision 1 angioplasty
10 48 angioplasty 10 angioplasty
11 8 angioplasty 3 angioplasty
12 60 revision 48 thrombectomy
13 28 thrombectomy 1 thrombectomy
14 20 none — revision
15 21 none — angioplasty
16 12 angioplasty 3 (patent)
17 24 none — LTF
18 23 thrombectomy 5 thrombectomy
19 24 revision 3 thrombectomy
20 21 angioplasty 15 (patent)
21 11 thrombectomy 1 thrombectomy
22 10 angioplasty 6 thrombectomy
23 36 thrombectomy 1 revision
24 25 none — (patent)
25 31 none — thrombectomy
26 7 none — angioplasty
27 17 thrombectomy 2 angioplasty
28 20 angioplasty 6 angioplasty
29 8 none — thrombectomy
30 7 thrombectomy 4 revision
Interval between previous procedure and angioplasty
65
717
78
274
159
156
74
99
180
239
194
172
229
93
64
731
53
20
384
653
61
170
23
247
386
357
112
204
143
83
initiating
studyb LTF lost to follow-up
This study was designed as a controlled investigation of a
large group of dialysis patients having a single type of stenotic
lesion using specific criteria to define success.
The graft-vein lesion was chosen for this study because it is
the most common type of stenosis affecting dialysis access
grafts, occurring in 58% of cases. It also tends to be more
homogeneous than the venous lesions that occur proximal
(upstream) to the graft [9]. The appropriate control group for
patients receiving stents following PTVA should be comparable
patients treated with PTVA only. Evaluation of the character-
istics of the treatment group and of the concurrent control
group demonstrated that they were comparable prior to PTVA
and in their response to therapy. Furthermore, a comparison of
the treatment and concurrent control groups with the historical
control group demonstrated that both were typical of the total
population of dialysis patients having this specific lesion.
From a clinical viewpoint, the criteria used to determine the
endpoint for each patient in a study such as this should be the
duration of the clinical utility of their treated graft for dialysis
access. Whether it be thrombosis, the need for surgical revi-
sion, or the need for a repeat angioplasty, at that point the stent
has failed. To be successful, this device must preserve patency
and function without the need for further invasive procedure
and do it longer than would be the case were the stent not
present.
Using these criteria, it appears that the Gianturco stent is not
of value in treating the graft-vein stenosis affecting PTFE
dialysis access grafts.
Several secondary conclusions can be drawn from the data
generated by this study. This stent can be easily applied and,
when barbs are used to prevent migration, is associated with a
very low level of complication. It is not immediately thrombo-
genic in dialysis patients and causes no obstruction to flow. The
stent does not interfere with subsequent PTVA although it is
generally entangled when a Fogarty balloon catheter is used for
thrombectomy.
Several important questions concerning the use of endovas-
cular stents in this type of clinical application remain unan-
swered and require further investigation. Even though there
was no significant difference between the incidence of throm-
bosis in the treatment group and the concurrent control group,
we cannot conclude that graft loss due to thrombosis was
related to the lesion that had previously been treated in either
group. A number of factors unrelated to stenosis can lead to the
formation of a thrombus within the graft [7]. Since thrombec-
tomy generally resulted in the loss of the stent, it was not
possible to evaluate the status of the device after therapy. In the
four cases requiring a repeat VFVA in which the obstructing
lesion within the stent appeared soft, the possibility of fibrin
deposition must be considered. Whether the success of treat-
ment with an endovascular stent could be prolonged by using
chronic anticoagulation or anti-platelet agents is a question that
should be evaluated.
Although the graft-vein anastomosis is the most common site
for stenosis in these patients, venous lesions are very frequent
and some patients have both [9]. It is very likely that the
pathophysiology of these venous lesions is different, resulting
from phlebosclerosis and perivenous fibrosis. This process
results in constriction, in contrast to the intraluminal prolifera-
tion of pseudointimal hyperplasia, which accounts for at least
part of the process which occurs at the graft-vein anastomosis.
This latter lesion can occur internal to the stent whose function
is to support the wall of the vessel through outward pressure.
Although the homogeneity and frequency of the graft-vein
anastomosis stenosis make it an appropriate place to start in
evaluating the efficacy of endovascular stents, the nature of this
device is such that it may be more effective in preventing the
constricting lesion. Consistent with this speculation is the fact
that Quinn et al [121 reported better results with large veins than
with the two graft-vein anastomosis lesions in their series. We
cannot conclude that the failure of the Gianturco stent to be
effective with one type of lesion indicates a likelihood of failure
with others. We feel that further study is warranted, but this
must involve controlled study of groups of patients with com-
parable lesions.
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